Canada
· Delayed Price · Currency is CAD Rapid Dose Therapeutics Statistics
Total Valuation
Rapid Dose Therapeutics has a market cap or net worth of CAD 18.70 million. The enterprise value is 21.15 million.
| Market Cap | 18.70M |
| Enterprise Value | 21.15M |
Important Dates
The next estimated earnings date is Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Rapid Dose Therapeutics has 124.64 million shares outstanding. The number of shares has increased by 5.85% in one year.
| Shares Outstanding | 124.64M |
| Shares Change (YoY) | +5.85% |
| Shares Change (QoQ) | +12.54% |
| Owned by Insiders (%) | 10.81% |
| Owned by Institutions (%) | n/a |
| Float | 111.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.94 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.23 |
| EV / Sales | 17.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -113.93% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.36% in the last 52 weeks. The beta is 0.70, so Rapid Dose Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +36.36% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 49.28 |
| Average Volume (20 Days) | 20,557 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rapid Dose Therapeutics had revenue of CAD 1.18 million and -5.00 million in losses. Loss per share was -0.05.
| Revenue | 1.18M |
| Gross Profit | 702,508 |
| Operating Income | -3.54M |
| Pretax Income | -5.00M |
| Net Income | -5.00M |
| EBITDA | -3.30M |
| EBIT | -3.54M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 113,062 in cash and 2.57 million in debt, giving a net cash position of -2.46 million or -0.02 per share.
| Cash & Cash Equivalents | 113,062 |
| Total Debt | 2.57M |
| Net Cash | -2.46M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -3.31M |
| Book Value Per Share | -0.03 |
| Working Capital | -2.18M |
Cash Flow
| Operating Cash Flow | -2.78M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 59.60% |
| Operating Margin | -300.72% |
| Pretax Margin | -423.92% |
| Profit Margin | n/a |
| EBITDA Margin | -279.98% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Rapid Dose Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.85% |
| Shareholder Yield | -5.85% |
| Earnings Yield | -30.41% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Rapid Dose Therapeutics has an Altman Z-Score of -36.4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -36.4 |
| Piotroski F-Score | n/a |